Kornimate/medical-research-clean huggingface dataset:
longitudinal tspo pet imaging with [18f]dpa-714 in ppmi (ppmi dpa-714 pet imaging)

Conditions: Parkinson Disease

Summary: the overall goal of this protocol is to investigate \[18f\]dpa-714 binding in prodromal and early manifest parkinson's disease (pd) and to determine the baseline and change from baseline in \[18f\]dpa-714 binding in pd participants during a 24-month interval. primary objectives * to compare \[18f\]dpa-714 binding in prodromal and manifest pd and healthy volunteers. * to determine the longitudinal change in \[18f\]dpa-714 during a 24-month interval for prodromal and early initially untreated pd participants. secondary objectives * to evaluate the correlation between baseline \[18f\]dpa-714 and ppmi clinical and biomarker outcomes. * to evaluate the correlation between the longitudinal change of \[18f\]dpa-714 and ppmi clinical and biomarker outcomes * to acquire safety data following injection of \[18f\]dpa-714


Eligibility criteria:
inclusion criteria: * a prodromal pd and healthy participant enrolled in ppmi clinical protocol * a pd participant enrolled in ppmi clinical protocol who has not started symptomatic treatment at time of enrollment or in the first 2 years of participation. * able to provide informed consent * must have screening genetic testing documenting high binder at the at the known tspo gene polymorphism (rs6971) * male or female (females must meet additional criteria specified below, as applicable) • females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \[18f\]dpa-714 * non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to pet scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). * highly effective method of birth control is defined as practicing at least one of the following: a birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (iud) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable. * females of childbearing potential must not be pregnant, breastfeeding or lactating. * includes a negative urine pregnancy test prior to injection of \[18f\]dpa-714 on day of pet scan. exclusion criteria: * exposure to a total effective dose equivalent of 50 millisievert (msv) for the whole body, which is the annual limit established by the us code of federal regulations , during the past year. * any other medical or psychiatric condition or lab abnormality, which in the opinion of the site investigator might preclude participation.
spinal bupivacaine/morphine in laparoscopic gastro-intestinal surgery

Conditions: Spinal Bupivacaine/Morphine in Laparoscopic Surgery

Summary: the objective of this study is to determine if a single spinal shot of morphine can decrease post-operative opioid-use, and thereby decrease opioid side-effects and lead to a quicker recovery after surgery.

we expect that in laparoscopic gastro-intestinal surgery, a single shot spinal with bupicavaine/morphine will result in a better analgesia in hte first 48 hours. herby the patients will require less systemic opioids, which will decrease the side-effects. furthermore, we expect the patients to recover quicker and show an earlier mobilisation and a shorter hospital stay. the objective of this study is to determine if a single spinal shot of morphine can decrease post-operative opioid-use, and thereby decrease opioid side-effects and lead to a quicker recovery after surgery.

Eligibility criteria:
inclusion criteria: * laparoscopic gastro-intestinal surgery exclusion criteria: * bariatric surgery, gastric surgery, rectal surgery, kidney failure, aorta-valve stenosis, coagulation disorders, emergency surgery

Keywords: spinal morphine laparoscopic gi-surgery post-operative pain
fascial versus standard neck dissection in patients with n1b papillary thyroid carcinoma

Conditions: Patients With Papillary Thyroid Cancer and N1b Status

Summary: optimal surgical technique for neck dissection (lnd) in thyroid carcinoma remains a subject of debate. fascial nd (fnd) implies the removal of the superficial and middle layers of the deep cervical fascia en bloc with lymph-nodes containing fibro-fatty tissue (levels iia-vb and vi-vii for cn1b patients). this retrospective cohort study was designed to compare fnd with standard, non-fascial, selective nd (snd).

in thyroid cancer patients, lymph node dissection includes a comprehensive removal of all the target nodal basins: anterior cervical compartment (level vi) and the superior mediastinal nodes that can be reached via cervical incision (level vii) in cnd, and levels iia-vb in lnd. clearance of those levels without including the enveloping fasciae in the specimen is referred to hereafter as standard neck dissection (snd), as it is the most common technique applied for thyroid tumors. in fascial neck dissection, the comprehensive clearance of the target basins is achieved by following the planes of coalescence of the cervical fascial layers. those are avascular and enable the removal of the target nodes en bloc with their investing fascial layers. the aim of this retrospective study was to compare the outcomes between fascial and standard approach in n1b ptc patients that underwent surgery for n1b papillary thyroid cancer. the primary objective was to achieve a significantly higher nodal yield by applying the fascial neck dissection technique and reduce rates of early loco-regional recurrence. secondary objectives were the evaluation of short and long-term post-operative complications and the cosmetic result.

Eligibility criteria:
inclusion criteria: patients who met all the following criteria were eligible for inclusion in this retrospective evaluation: * male or female patients, living or deceased, aged 18 years or older at the time of operation * unilateral (left/right) or bilateral lateral neck dissection along with central neck dissection * patients with papillary cancer, pn1b. this excludes patients with other types of thyroid cancer (e.g., medullary, follicular, and anaplastic); * patients that underwent central and/or lateral neck dissection as a primary intervention. this excludes patients with any previous operation for thyroid disease involving any type of lymph node dissection. exclusion criteria: patient's age \< 18 years, patients that underwent previous neck dissection of any type and patients who refused or were unable to provide adequate follow up data.
efficacy of kinesiotaping during rehabilitation following total knee replacement surgery

Conditions: Total Knee Replacement; Postoperative Recovery; Rehabilitation Outcome

Summary: the aim of this study was to examine the efficacy of kinesiotaping (kt) within postoperative rehabilitation after total knee replacement (tkr) surgery by determining whether kt enhances early postoperative outcomes, in terms of reduction of swelling, pain relief and improvement in the function of the knee joint, compared to conventional rehabilitation without the use of kt.

kinesiotaping and rehabilitation after total knee replacement the effectiveness of kinesiotaping (kt) in postoperative rehabilitation remains scientifically unproven, despite its widespread use. kt is believed to reduce pain and swelling, improve muscle function, and enhance joint mobility by promoting blood flow and lymphatic drainage. however, high-quality studies assessing its efficacy, particularly following total knee replacement (tkr), are lacking. aim of the study the aim of this study is to demonstrate that kt, when applied during inpatient rehabilitation after tkr, improves clinical outcomes compared to standard rehabilitation without kt. specifically, the investigators aim to show that: kt reduces postoperative swelling and pain, thereby enhancing knee function. kt promotes faster recovery of muscle strength and range of motion. kt shortens the time needed to achieve key postoperative milestones, allowing for a more effective rehabilitation process.

Eligibility criteria:
inclusion criteria: * adults aged ≥18 years. * patients who have undergone primary total knee replacement (tkr) with uncomplicated wound conditions. * no signs of infection post-surgery. * ability to understand study procedures and complete required questionnaires. exclusion criteria: * revision tkr surgeries. * early postoperative complications (e.g., wound healing disorders, deep infections, thrombosis). * severe comorbidities (e.g., heart failure nyha class 3-4, renal insufficiency grade 3-4, chronic lymphedema, dermatological conditions). * known allergies to kinesiotaping (kt) or adhesive materials. * neurological or neuromuscular disorders. * cognitive impairments (e.g., dementia) affecting compliance.

Keywords: kinesiotaping total knee replacement rehabilitation knee joint function pain relief
reducing brief thermal and electrical pain (four study days)

Conditions: Pain

Summary: ultimately, the purpose of the present study is to help improve pain control in burn patients during wound care and physical therapy, where pain levels with opioids alone are often excessively high. this study measures how much virtual reality pain distraction reduces pain compared to traditional opioid pain meds, and whether there is additional pain reduction when virtual reality distraction + opioids are combined. in addition to studying the amount of pain reduction, this study will also measure side effects (if any) of the two treatments (virtual reality pain distraction and opioids) alone and when combined. healthy volunteers will be recruited from advertisements will undergo a trial of the pain testing. they will receive a series of brief stimuli (at a painful but tolerable safe intensities they select and approve during baseline testing), separated by intervals of no pain. participants will rate how much pain they felt after each brief stimulus, and will fill out side effects questionnaires after finishing the pain session. subjects will participate in each of the four conditions in which the order is randomized. * no opioids (0ng/ml hydromorphone) + no virtual reality snow world distraction * no opioids + yes virtual reality snow world distraction * moderate dose of pain medicine (4ng/ml hydromorphone) + no virtual reality * moderate dose of pain medicine + yes virtual reality snow world distraction it is our hypothesis that vr distraction + opioids will show a reduced perception of pain in subjects more than opioids alone or no intervention (control).

in this study, healthy volunteers aged 18-45 who sign up after seeing a flyer or web posting are screened for exclusion via telephone interview, and if eligible, a health background interview. initial contact will come from the subject's response to recruitment materials. subjects may withdraw at any time. these safe laboratory studies with healthy volunteers are designed to help us figure out how to maximize the effectiveness of virtual reality when used with severe burn patients at harborview burn center

Eligibility criteria:
inclusion criteria: * healthy men and women 18-45 years old * normal height and weight ratio exclusion criteria: * women who are pregnant and nursing * history of substance abuse * access to opioids in the workplace * smokes cigarettes * history of medical problems with the following: heart, lungs, liver, kidneys, endocrine, neurologic, migraines, or psychiatric requiring medical intervention * anemia * chronic pain * allergy or hypersensitivity to opioids, velcro, or latex * severe motion sickness * unusual sensitivity or lack of sensitivity to pain * sensitive skin or feet

Keywords: pain distraction analgesic interventions burn patients
napoleon measurement of gastrojejunal anastomosis

Conditions: Gastric Bypass; Weight Regain

Summary: this is a clinical trial assessing the feasibility of the napoleon device for measuring the gastrojejunal anastomosis (gja). the study population is roux-en-y gastric bypass (rygb) patients with weight regain undergoing an endoscopy at bellevue hospital center or brigham and women's hospital. investigators aim for a sample size of up to 100 cases. for each case, endoscopists will first visually estimate the diameter of the gja by comparing its size to the upper endoscope. then, they will measure the gja with napoleon. investigators will compare the gja measurements performed using visual estimation and napoleon. a survey will be given to all endoscopists to assess the level of ease using napoleon.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. rygb patient with weight regain age 18-90 2. scheduled for an endoscopy 3. willingness and ability to provide informed consent exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. history of prior endoscopies with complications
assessment of quality of life and treatment times for patients with invasive type breast cancer in martinique

Conditions: Breast Neoplasms; Quality of Life; Survivorship

Summary: cancer and its treatments can be factors that alter the quality of life of patients. the induced alteration of the quality of life can influence compliance and impact survival. considering the after-effects of the treatment, carrying out such a survey will provide for the first time precise information on the main determinants of the quality of life as well as on the care pathway of patients with invasive breast cancer in the martinique region.

breast cancer is the second most common cancer in the west indies and the leading cancer in women. with 215 new cases in guadeloupe, 204 in martinique and 56 in french guiana each year, it accounts for 37%, 33% and 26% of incident cancer cases in women respectively, but also affects men. its incidence, lower than in france, is increasing over the period 2008-2014. the diagnostic and therapeutic management of cancer can have an impact on the quality of life of patients, taking into account the adverse effects occurring during and after treatment, both in the short and long term. the european organisation for research and treatment of cancer (eortc) has developed a series of questionnaires to assess the quality of life of cancer patients, including a general questionnaire (qlq-c30) and specific modules for breast cancer (eortc breast (eortc qlq-br23)) with the objective of improving professional practices.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age residing in martinique with invasive breast cancer diagnosed from 2020 (single tumor at diagnosis) * patients who have read the information note and have indicated that they do not wish to participate in the study * patient with social security coverage. exclusion criteria: * refusal to participate * patient with insitu breast cancer * patient with a second cancer * patient with cancer within 5 years prior to inclusion * patient who could not answer quality of life questionnaires * patient not fluent in french * person under legal protection (safeguard of justice, guardianship, curators , etc.).

Keywords: breast cancer quality of life survivorship survival french west indies
a study of limited heart monitoring during non-anthracycline trastuzumab-based therapy in breast cancer patients

Conditions: Breast Cancer

Summary: the purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.


Eligibility criteria:
inclusion criteria: * age \>/= 18 years * newly diagnosed histologically confirmed primary invasive breast carcinoma (stage i-iv) * pathologically confirmed her2-positive breast cancer * planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last weeks with a planned duration of at least 12 months. * normal lv systolic function (ef greater than or equal to the institutional lower limit of normal) * william and able to comply with the requirements of the protocol exclusion criteria: * planned to receive an anthracycline-based regimen * prior history of treatment with anthracycline chemotherapy * history of cardiovascular including cardiomyopathy, heart failure, or any other clinically significant cardiovascular disease (as determined by the investigator) * uncontrolled hypertension, defined as systolic blood pressure \>/= 160 mmhg and/or diastolic blood pressure \>/= 90 mmhg (as determined by the investigator)

Keywords: non-anthracycline trastuzumab trastuzumab memorial sloan kettering cancer center 19-045
what are the effects of fibrinogen concentrate administration on biological parameters

Conditions: Hemorrhage

Summary: the fibrinogen concentrate are given since 50 years with the dose of 2g for a afibrinogenemia. but this dose has been fixed 40 years ago and from now nobody discuss this quantity. through this retrospective study the investigators tried to explore the evolution of blood test after a prescription of fibrinogen concentrate

the fibrinogen concentrate are given since 50 years with the dose of 2g for a afibrinogenemia. but this dose has been fixed 40 years ago and from now nobody discuss this quantity. through this retrospective study the investigators tried to explore the evolution of blood test after a prescription of fibrinogen concentrate.

Eligibility criteria:
inclusion criteria: * all patient who received fibrinogen concentrate exclusion criteria: * none
reversal of the antithrombotic action of new oral anticoagulants

Conditions: Thrombosis; Anticoagulant-induced Bleeding; Anticoagulant Overdosage; Hemorrhage

Summary: the main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants. 1. to determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on platelets and coagulation mechanisms under flow conditions. 2. to evaluate the ability of the concentrates containing coagulation factors (pccs and fviia) to reverse the effects induced by the new anticoagulants. these studies will be carried out ex vivo in blood samples obtained from healthy volunteers undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous clinical trials.

there is a lack of information on antidotes that could reverse the effects of new oral anticoagulants in patients that require a rapid restoration of their impaired hemostatic mechanisms. the present study seeks to improve the security and efficacy of the clinical practice with the new generation of oral anticoagulants. objectives: 1. to assess the action of new oral anticoagulants (dabigatran y rivaroxaban) on hemostasis with specific interest on possible interference with platelet interactions and coagulation mechanisms under flow conditions; 2. to evaluate comparatively the effects of coagulation factor concentrates of established efficacy (prothrombin complexes and rfviia) to reverse the alterations of hemostasis parameters induced by the new anticoagulants. methodology: studies will be performed ex vivo using blood samples from healthy individuals subjected to treatments with the new anticoagulants at doses of proven efficacy and safety (150mg/12 h for dabigatran and 20 mg/day for rivaroxaban). blood samples from the participants will be spiked "in vitro" with know concentrations of the coagulation factors. modifications in: * morphometric parameters (platelet deposition and fibrin formation) in perfusion studies under flow conditions; and * analytical tests evaluating changes in coagulation mechanisms (thrombin generation, ecarine and prothrombin times) will be determined.

Eligibility criteria:
inclusion criteria: * healthy volunteers ages from 21 to 60 years * approval informed consent exclusion criteria: * history of hepatic or kidney disease * previous history of hemorrhagic or thrombotic disease * pregnancy or breast feeding * concomitant use of drugs affecting hemostasis * use of medications of herbal treatments that could interfere with the pharmacokinetics or pharmacodynamics of the study drug (according to manufacturers label) * practice of risky sports (during the study period) * blood donation in the previous 3 months

Keywords: dabigatran rivaroxaban oral anticoagulants coagulation bleeding plasma concentrates
knot burial technique for rectus sheath closure

Conditions: Cesarean Section Complications

Summary: caesarean section is one of the most commonly performed abdominal operations on women in most countries of the world. its rate has increased markedly in recent years, and is about 20-25% of all child-births in most developed countries. the present study was a step to reduce postoperative pain in cesarean sections. because of the large number of women that undergo caesarean section, even small differences in post-operative morbidity rates due to different techniques could translate into improved health and significant savings of cost and health services resources. closing the rectus sheath in cesarean sections with the knots pricking through the skin causes significant postoperative pain, discomfort and delayed ambulation. no comments in literature regarding the best way for closing the rectus sheath in cesarean sections. aim/ objectives the aim of this study is to assess the efficacy of burying knots beneath the rectus sheath during cesarean section in reducing post operative pain and discomfort. study hypothesis: in women undergoing cesarean sections may or may not burying knots beneath the rectus sheath reduce the post operative pain and discomfort.

non absorbable and delayed absorbable monofilament materials require meticulous care to prevent knot slippage. one common problem that arises from use of these materials is the discomfort caused by the knot pricking through the skin. although this is a common problem after cesarean section, it is often overlooked and only very few preventive techniques have been described. this study is to assess the efficacy of burying knots beneath the rectus sheath during cesarean sections in reducing post operative pain and discomfort. type of study : a randomized controlled clinical trial. study setting :this study will be conducted at the department of obstetrics and gynecology at ain-shams university maternity hospital. study time: 2019. study population : the study population comprises pregnant women, fulfilling the inclusion criteria, attending to ain shams university maternity hospital, during the study period, who are planned for cesarean delivery.

Eligibility criteria:
inclusion criteria: * term pregnancy ( more than 37 weeks of gestation ) candidate for transverse incision elective cesarean delivery exclusion criteria: * patient with bmi \>30 and fat thickness \>3 cm. * patient with haemoglobin less than 10g/dl * patient with previous history of septic wound. * emergency lower segment cesarean section. * patients complaining of premature rupture of membrane. * patients need intra abdominal drains post cesarean sections * patients with established or gestational diabetes, coagulation defects, hemodynamic instability, septicemia or chorioamnionitis.